Accession Number:

AD1028763

Title:

Could HER2 Heterogeneity Open New Therapeutic Options in Patients with HER2-Primary Breast Cancer

Descriptive Note:

Technical Report,30 Sep 2015,29 Sep 2016

Corporate Author:

Memorial Sloan Kettering Cancer Center New York United States

Personal Author(s):

• Ulaner,Gary

Report Date:

2016-10-01

Pagination or Media Count:

9.0

Abstract:

The purpose of this study is to determine if targeted imaging with a HER2-targeting PET tracer can detect HER2-positive metastases inpatients with HER2-negative primary breast cancer. Twenty-three patients have been accrued to the trial. Nine patients demonstrated suspicious foci on 89Zr-trastuzumab PETCT. Two of nine patients with suspicious foci had biopsy-proven HER2-positive metastases. Thus, 89Zr-trastuzumab PETCT may detect HER2-positive metastases in patients with presumed HER2-negtive primary breast cancer. This is an initial proof-of-concept that targeted imaging may help identify patients eligible for targeted therapies. However, false-positive results limit the ability of 89Zr-trastuzumab to be translated into clinical use, and a more specific radiotracer will be needed.

Descriptors:

• breast cancer
• metastasis
• neoplasms
• therapeutics
• growth factors
• nuclear medicine
• POSITRON EMISSION TOMOGRAPHY

Subject Categories:

• Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE